GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » New Horizon Health Ltd (HKSE:06606) » Definitions » Treasury Stock

New Horizon Health (HKSE:06606) Treasury Stock : HK$-0 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is New Horizon Health Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. New Horizon Health's treasury stock for the quarter that ended in Jun. 2023 was HK$-0 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


New Horizon Health Treasury Stock Historical Data

The historical data trend for New Horizon Health's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Horizon Health Treasury Stock Chart

New Horizon Health Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Treasury Stock
- - - - -

New Horizon Health Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Treasury Stock Get a 7-Day Free Trial Premium Member Only - - - - -

New Horizon Health Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


New Horizon Health (HKSE:06606) Business Description

Traded in Other Exchanges
Address
400 Jiang’er Road, 13th Floor, T1 Building, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.

New Horizon Health (HKSE:06606) Headlines

No Headlines